| Document and Entity Information - shares | 3 Months Ended | |
| Mar. 31, 2019 | May 14, 2019 | |
| Document And Entity Information | ||
| Entity Registrant Name | SKINOVATION PHARMACEUTICAL INC | |
| Entity Central Index Key | 0001118072 | |
| Document Type | 10-Q | |
| Document Period End Date | Mar. 31, 2019 | |
| Amendment Flag | false | |
| Current Fiscal Year End Date | --12-31 | |
| Is Entity's Reporting Status Current? | Yes | |
| Is Entity Emerging Growth Company? | true | |
| Elected Not To Use the Extended Transition Period | false | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Common Stock, Shares Outstanding | 708,000 | |
| Document Fiscal Period Focus | Q1 | |
| Document Fiscal Year Focus | 2019 |
| Condensed Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
| Current Assets | ||
| Cash | $ 117 | $ 132 |
| Total Current Assets | 117 | 132 |
| Total Assets | 117 | 132 |
| Current Liabilities | ||
| Accounts payable | 12,000 | 7,700 |
| Notes payable | 199,421 | 198,321 |
| Accrued interest | 82,521 | 78,569 |
| Total Current Liabilities | 293,942 | 284,590 |
| Total Liabilities | 293,942 | 284,590 |
| Stockholders' Deficit | ||
| Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding | ||
| Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding | 708 | 708 |
| Additional paid in capital | 25,148 | 25,148 |
| Accumulated deficit | (319,681) | (310,314) |
| Total Stockholders' Deficit | (293,825) | (284,458) |
| Total Liabilities and Stockholders' Deficit | $ 117 | $ 132 |
| Condensed Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
| Statement of Financial Position [Abstract] | ||
| Preferred stock, par value | $ 0.001 | $ 0.001 |
| Preferred stock, authorized | 25,000,000 | 25,000,000 |
| Preferred stock, issued | 0 | 0 |
| Preferred stock, outstanding | 0 | 0 |
| Common stock, par value | $ 0.001 | $ 0.001 |
| Common stock, authorized | 50,000,000 | 50,000,000 |
| Common stock, issued | 708,000 | 708,000 |
| Common stock, outstanding | 708,000 | 708,000 |
| Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
| Mar. 31, 2019 | Mar. 31, 2018 | |
| Income Statement [Abstract] | ||
| REVENUES | ||
| EXPENSES | ||
| General and administrative | 5,415 | 5,575 |
| TOTAL EXPENSES | 5,415 | 5,575 |
| INCOME (LOSS) BEFORE OTHER EXPENSE | (5,415) | (5,575) |
| OTHER INCOME (EXPENSE) | ||
| Interest expense | (3,952) | (3,728) |
| Total other income (expense) | (3,952) | (3,728) |
| INCOME (LOSS) BEFORE INCOME TAXES | (9,367) | (9,303) |
| INCOME TAXES | ||
| NET INCOME (LOSS) | $ (9,367) | $ (9,303) |
| Basic and diluted net income (loss) per share | $ (0.01) | $ (0.01) |
| Weighted average shares outstanding | 708,000 | 708,000 |
| Condensed Statement of Stockholders’ Deficit (Unaudited) - USD ($) | Common Stock | Additional Paid-In Capital | Accumulated Deficit | Total |
| Beginning balance, shares at Dec. 31, 2017 | 708,000 | |||
| Beginning balance, amount at Dec. 31, 2017 | $ 708 | $ 25,148 | $ (281,726) | $ (255,870) |
| Net income (loss) | (9,303) | (9,303) | ||
| Ending balance, shares at Mar. 31, 2018 | 708,000 | |||
| Ending balance, amount at Mar. 31, 2018 | $ 708 | 25,148 | (291,029) | (265,173) |
| Beginning balance, shares at Dec. 31, 2018 | 708,000 | |||
| Beginning balance, amount at Dec. 31, 2018 | $ 708 | 25,148 | (310,314) | (284,458) |
| Net income (loss) | (9,367) | (9,367) | ||
| Ending balance, shares at Mar. 31, 2019 | 708,000 | |||
| Ending balance, amount at Mar. 31, 2019 | $ 708 | $ 25,148 | $ (319,681) | $ (293,825) |
| Condensed Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
| Mar. 31, 2019 | Mar. 31, 2018 | |
| Cash Flows from Operating Activities | ||
| Net income (loss) | $ (9,367) | $ (9,303) |
| Changes in assets and liabilities: | ||
| Increase in accounts payable | 4,300 | 5,575 |
| Increase in accrued interest | 3,952 | 3,728 |
| Net cash used by operating activities | (1,115) | |
| Cash Flows from Investing Activities | ||
| Net cash used by investing activities | ||
| Cash Flows from Financing Activities | ||
| Proceeds from notes payable | 1,100 | |
| Net cash provided by financing activities | 1,100 | |
| Increase (decrease) in cash | (15) | |
| Cash and cash equivalents at beginning of period | 132 | 547 |
| Cash and cash equivalents at end of period | 117 | 547 |
| Supplemental Cash Flow Information: | ||
| Cash paid for interest | ||
| Cash paid for income taxes | ||
| Condensed Financial Statements | 3 Months Ended |
| Mar. 31, 2019 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| Condensed Financial Statements | NOTE 1 – CONDENSED FINANCIAL STATEMENTS The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended March 31, 2019 and for all periods presented have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2018 audited financial statements as reported in its Form 10-K. The results of operations for the period ended March 31, 2019 are not necessarily indicative of the operating results for the full year ended December 31, 2019. |
| Going Concern | 3 Months Ended |
| Mar. 31, 2019 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| GOING CONCERN | NOTE 2 – GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies. |
| Accounts and Notes Payable | 3 Months Ended |
| Mar. 31, 2019 | |
| Payables and Accruals [Abstract] | |
| Accounts and Notes Payable | NOTE 3 – ACCOUNTS AND NOTES PAYABLE At March 31, 2109 and December 31, 2018, the Company had accounts payable of $12,000 and $7,700, respectively, and notes payable of $199,421 and $198,321, respectively, for services as well as cash advances received from unrelated parties. The notes payable bear interest at 8% and are due on demand. Accrued interest on the notes was $82,521 and $78,569 at March 31, 2019 and December 31, 2018 respectively. |
| Subsequent Events | 3 Months Ended |
| Mar. 31, 2019 | |
| Subsequent Events [Abstract] | |
| Subsequent Events | NOTE 4 – SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements. |
| Accounts and Notes Payable (Details Narrative) - USD ($) | 3 Months Ended | ||
| Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
| Payables and Accruals [Abstract] | |||
| Accounts payable for services and cash advances from unrelated parties | $ 12,000 | $ 7,700 | |
| Notes payable for services and cash advances from unrelated parties | $ 199,421 | 198,321 | |
| Interest rate on accounts payable-converted note | 8.00% | 8.00% | |
| Accrued interest | $ 82,521 | $ 78,569 | |
